Portal de Periódicos da CAPES

Enzymic hydroxylation of 5-fluoropyrimidines by aldehyde oxidase and xanthine oxidase

1966; Elsevier BV; Volume: 15; Issue: 3 Linguagem: Inglês

10.1016/0006-2952(66)90314-5

1873-2968

David G. Johns, Alan C. Sartorelli, Joseph R. Bertino, A.T. Iannotti, Barbara A. Booth, Arnold D. Welch,

Cancer, Hypoxia, and Metabolism

5-Fluorouracil (5-FU) is an effective antitumor agent used in treating various cancers. Because of its metabolism by intestinal and other cells, 5-FU has an inconsistent bioavailability that limits its oral use. 5-Fluoro-2-pyrimidinone (5-FP), a 5-FU prodrug, was synthesized and found to be converted to 5-FU by aldehyde oxidase, an enzyme present in high concentrations in the livers of mice and humans but not in the gastrointestinal tract. Using BDF1 mice, the pharmacokinetics of 5-FP were studied and compared with those of 5-FU. The bioavailability of 5-FP given orally was 100% at a dosage of 25 mg/kg and 78% at a dosage of 50 mg/kg. The half-lives of both doses of 5-FP were at least 2-fold longer than the half-lives of the same doses of 5-FU, and the clearance rates of 5-FP were 3-fold slower. 5-FP was converted rapidly to 5-FU in vivo. The resulting 5-FU was measured at a steady-state level of 40–70 μM in plasma, at a dosage of 25 mg/kg, that was sustained for at least 4 hr. Also, when given orally, 5-FP was shown to have potent activity against Colon 38 tumor cells and P388 leukemia cells in mice. The therapeutic index of 5-FP was similar to that of 5-FU in these mouse tumor models. The potential clinical use of 5-FP as a prodrug of 5-FU should be considered.